Monopar to Present at the Jefferies Radiopharma Innovation Summit
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced that Dr. Chandler Robinson, the CEO, will present at the Jefferies Radiopharma Innovation Summit on April 3, 2023, from 1:00 to 1:30 pm at the Jefferies Conference Center in NYC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced that Dr. Chandler Robinson, the CEO, will present at the Jefferies Radiopharma Innovation Summit on April 3, 2023, from 1:00 to 1:30 pm at the Jefferies Conference Center in NYC.
The company focuses on developing therapeutics aimed at extending life and improving the quality of life for cancer patients. Their pipeline includes camsirubicin (Phase 1b) for advanced soft tissue sarcoma and MNPR-101 for radiopharmaceutical use in advanced cancers. Monopar is committed to enhancing cancer patient care through innovation.
Details
News Market Reaction – MNPR
The recorded move for MNPR in the trading session of this news was -51.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week.
Presentation Details:
Date: April 3, 2023
Time: 1:00 – 1:30 pm
Location: Jefferies Conference Center, NYC, New York
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.